MEI Pharma (MEIP)
(Delayed Data from NSDQ)
$3.12 USD
+0.01 (0.32%)
Updated May 21, 2024 03:56 PM ET
After-Market: $3.12 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth A Momentum A VGM
Price, Consensus and EPS Surprise
MEIP 3.12 +0.01(0.32%)
Will MEIP be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MEIP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MEIP
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Lags Revenue Estimates
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
MEIP: What are Zacks experts saying now?
Zacks Private Portfolio Services
AstraZeneca's (AZN) Capivasertib Gets FDA Nod for Breast Cancer
AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails
Pacira (PCRX) Gets FDA Nod for Exparel's Label Expansion
Other News for MEIP
12 Health Care Stocks Moving In Thursday's After-Market Session
Stifel Nicolaus Reaffirms Their Hold Rating on MEI Pharma (MEIP)
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
MEIP Stock Earnings: MEI Pharma Beats EPS for Q3 2024
MEI Pharma GAAP EPS of -$1.37 beats by $0.12